FDA-Approved HIV Medications

The Latest

Promo Image

Drug Interactions Fact Sheet

Introduction Drug List Glossary of Terms Anti-HIV Medications + Street Drugs: Some Cocktails Don't Mix


With the number of drugs available to treat HIV and with those that prevent or treat opportunistic infections (OIs), the pot...

Promo Image

Protease Inhibitors Appear More Likely to Cause Atherosclerosis Than NNRTIs

Most protease inhibitors (PIs) have been associated with abnormal lipid profiles and insulin resistance, whereas better lipid profiles (such as an increase in high-density lipoprotein [HDL]) are seen with non-nucleoside reverse transcriptase inhibi...

Promo Image

Confort Study Supports Switch From Protease Inhibitor to Nevirapine


It is clear now that all but the most recently approved protease inhibitors (PIs) cause more gastrointestinal side effects and adverse effects on lipid profiles during treatment than the non-nucleoside reverse transcriptase inhibitors (NN...

Promo Image

Tipranavir Reduces Concentrations of Other Protease Inhibitors

All protease inhibitors (PIs) are substrates, as well as inducers or inhibitors, of the CYP3A4 system. Combining PIs can either increase or decrease the concentration of each drug. While ritonavir (RTV, Norvir), a potent CYP3A4 inhibitor, is widely u...

Promo Image

Tenofovir and Abacavir Do Not Interact in Patients on Triple-Nucleoside Regimens

Last year's 2nd IAS Conference in Paris will be remembered in part for the series of presentations showing the early failure of regimens containing the triple-nucleoside combination of lamivudine (3TC, Epivir), abacavir (ABC, Ziagen) and tenofovir (T...

Promo Image
Conference Coverage

Making Right Turns in the HIV Pharmacology Maze: 5th International Workshop on Clinical Pharmacology of HIV Therapy

Introduction How Much Does the Host Matter? Pharmacology News on New Antiretrovirals Drug-Drug Interactions -- Good, Bad, or Neither References


All roads lead to Rome, they say. But once you get there, none of them leads anyw...

Promo Image

New HIV Protease Inhibitors: New Options in the PI Class for Treatment-Naive Persons

Introduction Benefits of Early Protease Inhibitors Limitations of Early Protease Inhibitors Challenges to Protease Inhibitors: Non-Nucleoside RT Inhibitors The Rise of Boosted PIs Therapeutic Challenges and New Protease Inhibitors New P...

Promo Image

Case Study: Drug-Drug Interactions Associated With the Use of Antiretroviral Therapy


A 30 year-old male inmate with class B3 HIV/AIDS and a history of injection drug use, idiopathic thrombocytopenic purpura (ITP), upper gastrointestinal bleeding, and chronic untreated hepatitis C presents to you for an initial evaluation one we...

Promo Image

Dual-PI Regimen Preferred Over Single-PI Regimen After Initial PI Failure

The selection of a second treatment regimen after an initial treatment failure is becoming easier as our armamentarium of antiretroviral agents expands. Currently, for patients failing an initial NNRTI-based regimen, the decision for a second regimen...

Promo Image

Gilead Aims to Begin Evaluation of New Protease Inhibitor

Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a re...